HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
RXRX
Recursion Pharmaceuticals Inc - Class A
Healthcare Biotechnology · Utah, USA · Reports in usd
Market Cap: $1.75B
Market Cap
$1.75B
Enterprise Val
$1.16B
P/E Ratio
-3.13
P/B Ratio
1.71
Trailing PEG (1Y)
0.06
As Of
May 7, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$1.02B
Gross Margin-92.99%
Profit Margin-92.99%
Return on Equity-54.32%
Return on Assets-40.60%
Current Ratio5.47
Debt/Equity0.07
LT Debt/Equity0.05
Revenue Per Share0.01

Income Statement

Mar 31, 2026
Revenue$6.5M
Cost of Revenue$12.5M
Gross Profit-$6.0M
R&D$87.9M
SG&A$34.6M
Operating Expenses$122.5M
Operating Income-$128.5M
Interest Expense$0.00
Tax Expense-$4.6M
Net Income-$117.5M
EPS (Basic)$-0.22
EPS (Diluted)$-0.22
EBIT-$122.1M
EBITDA-$97.2M
Consolidated Income-$117.5M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$660.0M
Accounts Receivable$13.6M
Inventory$0.00
Current Assets$709.6M
LT Investments$5.2M
Property, Plant & Equipment$157.3M
Intangibles$454.2M
Non-Current Assets$630.0M
Total Assets$1.34B
Accounts Payable$20.3M
Current Debt$22.4M
Current Liabilities$129.7M
LT Debt$50.0M
Non-Current Liabilities$185.1M
Total Liabilities$314.8M
Total Debt$72.4M
Retained Earnings-$2.19B
Shareholder Equity$1.02B
Shares Outstanding527,397,997

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$81.1M
Investing Cash Flow-$338.0K
Financing Cash Flow-$3.5M
CapEx-$258.0K
Free Cash Flow-$81.4M
Depreciation & Amort.$24.9M
Stock-Based Comp$22.2M
Acquisitions / Disposals$0.00
Investment Activity$0.00
Debt Issued/Repaid-$2.2M
Equity Issued/Repaid-$1.3M
Dividends Paid$0.00
Net Change in Cash-$88.7M
Data cached · Meta live · Daily live · Statements live · TTL 24h